CF
PEARW

Cantor Fitzgerald’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Cantor Fitzgerald’s Portfolio PEARW Stock Details PEARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-79,605
Closed -$63K – 874
2022
Q1 		$63K Sell
79,605
-100
-0.1% -$70 ﹤0.01% 321
2021
Q4 		$48K Buy
+79,705
New +$80.9K ﹤0.01% 348

Other funds holding PEARW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return

Cantor Fitzgerald's PEARW Position: Q2 2022 in Review

Cantor Fitzgerald sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2022, closing a stake of 79,605 shares — an estimated $63K sold.

Cantor Fitzgerald first reported a position in PEARW in Q4 2021 and held it in 2 quarters. The position peaked at $63K in Q1 2022. 37 funds tracked by Wall St. Rank hold PEARW as of Q2 2022.

  • Cantor Fitzgerald reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2022 after selling out during the quarter.
  • Cantor Fitzgerald sold 79,605 Pear Therapeutics, Inc. Warrant shares in Q2 2022, an estimated $63K.
  • Cantor Fitzgerald first reported a position in Pear Therapeutics, Inc. Warrant in Q4 2021 and held it in 2 quarters.
  • Cantor Fitzgerald's Pear Therapeutics, Inc. Warrant position peaked at $63K in Q1 2022.
  • 37 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2022.

Based on Cantor Fitzgerald's 13F filing for Q2 2022, filed 15 Aug 2022.